Linked Life Data

2134116

Source:http://linkedlifedata.com/resource/pubmed/id/2134116

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2
pubmed:dateCreated
1992-4-13
pubmed:abstractText
A double-blind placebo-controlled between-patient study was carried out to assess the effects of oxiracetam (CGP 21690E) on memory function in patients with epilepsy. During a 12-week period, either oxiracetam (800 mg t.i.d.) or placebo was given to 30 patients. Twenty-four of the patients had a partial epilepsy. Most patients were on monotherapy carbamazepine. Effect of oxiracetam on memory and related cognitive functions were assessed, using a computerized neuropsychological testing method, while concomitant electrophysiological changes were investigated with routine EEG registration, power spectrum analysis and auditory evoked event-related potentials (P300). Subjective evaluation of well-being was quantified with a mood rating scale. The results did not show any meaningful changes in memory function. This finding is in line with the subjective patient reports and the P300 measures.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
0302-282X
pubmed:author
pubmed:issnType
Print
pubmed:volume
24
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
90-101
pubmed:dateRevised
2006-7-19
pubmed:meshHeading
pubmed:articleTitle
Double-blind placebo-controlled, neuropsychological and neurophysiological investigations with oxiracetam (CGP 21690E) in memory-impaired patients with epilepsy.
pubmed:affiliation
Institute voor Epilepsiebestrijding; Meer & Bosch/De Cruquiushoeve, Heemstede, Nederland.
pubmed:publicationType
Journal Article, Clinical Trial, Randomized Controlled Trial